<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs) are generally thought to be diseases of elderly patients, younger patients also have rarely been diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This is a report of the clinical, morphologic and cytogenetic features of 52 cases of primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> occurring in adults under the age of 50 years </plain></SENT>
<SENT sid="2" pm="."><plain>Cases secondary to chemotherapy or radiotherapy were excluded </plain></SENT>
<SENT sid="3" pm="."><plain>There were 31 males and 21 females </plain></SENT>
<SENT sid="4" pm="."><plain>The median age at presentation was 39 years (range, 18 to 49 years) </plain></SENT>
<SENT sid="5" pm="."><plain>The interval between <z:hpo ids='HP_0003674'>onset</z:hpo> of symptoms and diagnosis was brief (median, 4 weeks; range, 1-32 weeks) </plain></SENT>
<SENT sid="6" pm="."><plain>Of the 49 patients for whom information about duration of symptoms was available, 13 (27%) were asymptomatic </plain></SENT>
<SENT sid="7" pm="."><plain>Forty-two (81%) of the patients were classified using FAB criteria for blood and bone marrow <z:mp ids='MP_0000002'>morphology</z:mp>: <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), 11; <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>), four; <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), 12; <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>), three; <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>), 12 patients </plain></SENT>
<SENT sid="8" pm="."><plain>Ten patients could not be categorized </plain></SENT>
<SENT sid="9" pm="."><plain>Abnormalities involving chromosome 7 was the most frequent cytogenetic abnormality (31%) </plain></SENT>
<SENT sid="10" pm="."><plain>Partial chromosomal deletion and chromosome gain were also common abnormalities (22% and 9%, respectively) </plain></SENT>
<SENT sid="11" pm="."><plain>Translocations accounted for only 9% of the main cytogenetic abnormalities encountered in this patient population </plain></SENT>
<SENT sid="12" pm="."><plain>For the 49 patients for whom information regarding <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> transformation was available, 23 (47%) progressed to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, with an overall median time to progression of 2 months (range 3 weeks to 3 years) </plain></SENT>
<SENT sid="13" pm="."><plain>In each category except for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, approximately half of the patients progressed, with a slightly less median time to progression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> than for the other subtypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>Thirteen patients underwent bone marrow transplantation at the time of presentation of their disease </plain></SENT>
</text></document>